company background image

Jacobson Pharma SEHK:2633 Stock Report

Last Price


Market Cap







05 Oct, 2022


Company Financials
2633 fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance2/6
Financial Health6/6

2633 Stock Overview

Jacobson Pharma Corporation Limited, through its subsidiaries, produces, markets, and sells generic drugs and branded healthcare products in Hong Kong, Mainland China, Macau, Singapore, and internationally.

Jacobson Pharma Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Jacobson Pharma
Historical stock prices
Current Share PriceHK$0.80
52 Week HighHK$0.94
52 Week LowHK$0.43
1 Month Change-11.11%
3 Month Change2.56%
1 Year Change29.03%
3 Year Change-23.81%
5 Year Change-62.96%
Change since IPO-52.38%

Recent News & Updates

Sep 25
Jacobson Pharma (HKG:2633) Is Increasing Its Dividend To HK$0.0268

Jacobson Pharma (HKG:2633) Is Increasing Its Dividend To HK$0.0268

Jacobson Pharma Corporation Limited ( HKG:2633 ) has announced that it will be increasing its dividend from last year's...

Sep 16
Should Shareholders Reconsider Jacobson Pharma Corporation Limited's (HKG:2633) CEO Compensation Package?

Should Shareholders Reconsider Jacobson Pharma Corporation Limited's (HKG:2633) CEO Compensation Package?

Jacobson Pharma Corporation Limited ( HKG:2633 ) has not performed well recently and CEO Derek Sum will probably need...

Jul 28
Jacobson Pharma's (HKG:2633) Shareholders Will Receive A Bigger Dividend Than Last Year

Jacobson Pharma's (HKG:2633) Shareholders Will Receive A Bigger Dividend Than Last Year

The board of Jacobson Pharma Corporation Limited ( HKG:2633 ) has announced that it will be paying its dividend of...

Shareholder Returns

2633HK PharmaceuticalsHK Market

Return vs Industry: 2633 exceeded the Hong Kong Pharmaceuticals industry which returned -34.1% over the past year.

Return vs Market: 2633 exceeded the Hong Kong Market which returned -28.6% over the past year.

Price Volatility

Is 2633's price volatile compared to industry and market?
2633 volatility
2633 Average Weekly Movement6.9%
Pharmaceuticals Industry Average Movement5.9%
Market Average Movement6.5%
10% most volatile stocks in HK Market12.7%
10% least volatile stocks in HK Market3.2%

Stable Share Price: 2633 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: 2633's weekly volatility (7%) has been stable over the past year.

About the Company

20161,736Derek Sum

Jacobson Pharma Corporation Limited, through its subsidiaries, produces, markets, and sells generic drugs and branded healthcare products in Hong Kong, Mainland China, Macau, Singapore, and internationally. The company offers generic drugs for various therapeutic categories, including the respiratory, cardiovascular, central nervous system, gastrointestinal, genito-urinary, musculoskeletal, endocrine and metabolic, dermatological, anti-allergics, scar treatment, oral anti-diabetics, and anti-infective, as well as arsenic trioxide oral solutions, rosuvastatin tablets, and atorvastatin tablets. It also provides branded medicines; health and wellness products; and proprietary Chinese medicines, such as Po Chai pills, Ho Chai Kung Tji Thung San, Tong Tai Chung Woodlok oil, Flying Eagle Woodlok Oil, Saplingtan, Shiling oil, Contractubex, Doan's Ointment, and Col-gan tablets.

Jacobson Pharma Fundamentals Summary

How do Jacobson Pharma's earnings and revenue compare to its market cap?
2633 fundamental statistics
Market CapHK$1.53b
Earnings (TTM)HK$177.67m
Revenue (TTM)HK$1.60b


P/E Ratio


P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
2633 income statement (TTM)
Cost of RevenueHK$975.02m
Gross ProfitHK$620.52m
Other ExpensesHK$442.86m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date


Earnings per share (EPS)0.093
Gross Margin38.89%
Net Profit Margin11.14%
Debt/Equity Ratio45.4%

How did 2633 perform over the long term?

See historical performance and comparison



Current Dividend Yield


Payout Ratio
We’ve recently updated our valuation analysis.


Is 2633 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 3/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 2633?

Other financial metrics that can be useful for relative valuation.

2633 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.8x
Enterprise Value/EBITDA7.3x
PEG Ration/a

Price to Earnings Ratio vs Peers

How does 2633's PE Ratio compare to its peers?

2633 PE Ratio vs Peers
The above table shows the PE ratio for 2633 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average4.6x
2348 Dawnrays Pharmaceutical (Holdings)
1681 Consun Pharmaceutical Group
6600 SciClone Pharmaceuticals (Holdings)
2877 China Shineway Pharmaceutical Group
2633 Jacobson Pharma

Price-To-Earnings vs Peers: 2633 is expensive based on its Price-To-Earnings Ratio (8.6x) compared to the peer average (4.6x).

Price to Earnings Ratio vs Industry

How does 2633's PE Ratio compare vs other companies in the HK Pharmaceuticals Industry?

Price-To-Earnings vs Industry: 2633 is good value based on its Price-To-Earnings Ratio (8.6x) compared to the Hong Kong Pharmaceuticals industry average (8.8x)

Price to Earnings Ratio vs Fair Ratio

What is 2633's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

2633 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio8.6x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 2633's Price-To-Earnings Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of 2633 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 2633 (HK$0.8) is trading below our estimate of fair value (HK$3.77)

Significantly Below Fair Value: 2633 is trading below fair value by more than 20%.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Future Growth

How is Jacobson Pharma forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score


Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Jacobson Pharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Discover growth companies

  • Examine whether Jacobson Pharma is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
  • Jacobson Pharma competitive advantages and company strategy can generally be found in its financial reports archived here.

Past Performance

How has Jacobson Pharma performed over the past 5 years?

Past Performance Score


Past Performance Score 2/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 2633 has high quality earnings.

Growing Profit Margin: 2633's current net profit margins (11.1%) are lower than last year (12%).

Past Earnings Growth Analysis

Earnings Trend: 2633's earnings have declined by 4.1% per year over the past 5 years.

Accelerating Growth: 2633's earnings growth over the past year (2.3%) exceeds its 5-year average (-4.1% per year).

Earnings vs Industry: 2633 earnings growth over the past year (2.3%) underperformed the Pharmaceuticals industry 3.7%.

Return on Equity

High ROE: 2633's Return on Equity (6.3%) is considered low.

Discover strong past performing companies

Financial Health

How is Jacobson Pharma's financial position?

Financial Health Score


Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: 2633's short term assets (HK$1.2B) exceed its short term liabilities (HK$826.4M).

Long Term Liabilities: 2633's short term assets (HK$1.2B) exceed its long term liabilities (HK$971.2M).

Debt to Equity History and Analysis

Debt Level: 2633's net debt to equity ratio (27.4%) is considered satisfactory.

Reducing Debt: 2633's debt to equity ratio has reduced from 52.9% to 45.4% over the past 5 years.

Debt Coverage: 2633's debt is well covered by operating cash flow (30.3%).

Interest Coverage: 2633's interest payments on its debt are well covered by EBIT (11x coverage).

Balance Sheet

Discover healthy companies


What is Jacobson Pharma current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 3/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage


Current Dividend Yield

Dividend Yield vs Market

Jacobson Pharma Dividend Yield vs Market
How does Jacobson Pharma dividend yield compare to the market?
SegmentDividend Yield
Company (Jacobson Pharma)4.8%
Market Bottom 25% (HK)3.1%
Market Top 25% (HK)9.0%
Industry Average (Pharmaceuticals)2.9%
Analyst forecast in 3 Years (Jacobson Pharma)n/a

Notable Dividend: 2633's dividend (4.85%) is higher than the bottom 25% of dividend payers in the Hong Kong market (3.07%).

High Dividend: 2633's dividend (4.85%) is low compared to the top 25% of dividend payers in the Hong Kong market (9%).

Stability and Growth of Payments

Stable Dividend: 2633 has been paying a dividend for less than 10 years and during this time payments have been volatile.

Growing Dividend: 2633's dividend payments have increased, but the company has only paid a dividend for 6 years.

Earnings Payout to Shareholders

Earnings Coverage: With its reasonably low payout ratio (41.8%), 2633's dividend payments are well covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: With its low cash payout ratio (21.7%), 2633's dividend payments are well covered by cash flows.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average board tenure


Derek Sum (59 yo)





Mr. Kwong Yip Sum, also known as Derek, is Non-Executive Chairman of the Board at JBM (Healthcare) Limited since September 22, 2020. He joined the company and its subsidiaries September 22, 2020. With exte...

CEO Compensation Analysis

Derek Sum's Compensation vs Jacobson Pharma Earnings
How has Derek Sum's remuneration changed compared to Jacobson Pharma's earnings?
DateTotal Comp.SalaryCompany Earnings
Mar 31 2022HK$5mHK$3m


Dec 31 2021n/an/a


Sep 30 2021n/an/a


Jun 30 2021n/an/a


Mar 31 2021HK$5mHK$4m


Dec 31 2020n/an/a


Sep 30 2020n/an/a


Jun 30 2020n/an/a


Mar 31 2020HK$5mHK$4m


Sep 30 2019n/an/a


Jun 30 2019n/an/a


Mar 31 2019HK$5mHK$4m


Dec 31 2018n/an/a


Sep 30 2018n/an/a


Jun 30 2018n/an/a


Mar 31 2018HK$6mHK$4m


Dec 31 2017n/an/a


Sep 30 2017n/an/a


Jun 30 2017n/an/a


Mar 31 2017HK$11mHK$9m


Dec 31 2016n/an/a


Sep 30 2016n/an/a


Jun 30 2016n/an/a


Mar 31 2016HK$11mHK$11m


Compensation vs Market: Derek's total compensation ($USD663.83K) is above average for companies of similar size in the Hong Kong market ($USD308.74K).

Compensation vs Earnings: Derek's compensation has been consistent with company performance over the past year.

Board Members

Experienced Board: 2633's board of directors are considered experienced (6.5 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: 2633 insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

SEHK:2633 Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
08 Jul 22BuyHK$2,051,501Kwong Yip SumIndividual2,500,000HK$0.82
07 Jul 22BuyHK$1,092,141Kwong Yip SumIndividual1,400,000HK$0.78
06 Jul 22BuyHK$228,179Kwong Yip SumIndividual300,000HK$0.76
05 Jul 22BuyHK$508,130Kwong Yip SumIndividual700,000HK$0.73
04 Jul 22BuyHK$1,623,102Kwong Yip SumIndividual2,300,000HK$0.71
30 Jun 22BuyHK$717,003Kwong Yip SumIndividual1,000,000HK$0.72
15 Mar 22BuyHK$210,784Kwong Yip SumIndividual280,000HK$0.75
14 Mar 22BuyHK$267,300Kwong Yip SumIndividual330,000HK$0.81
11 Mar 22BuyHK$836,213Kwong Yip SumIndividual1,038,000HK$0.81
10 Mar 22BuyHK$253,025Kwong Yip SumIndividual320,000HK$0.79
09 Mar 22BuyHK$171,952Kwong Yip SumIndividual220,000HK$0.78
08 Mar 22BuyHK$456,621Kwong Yip SumIndividual578,000HK$0.79
07 Mar 22BuyHK$475,273Kwong Yip SumIndividual608,000HK$0.78
04 Mar 22BuyHK$938,521Kwong Yip SumIndividual1,188,000HK$0.79
03 Mar 22BuyHK$285,654Kwong Yip SumIndividual362,000HK$0.79
02 Mar 22BuyHK$316,001Kwong Yip SumIndividual400,000HK$0.79
01 Mar 22BuyHK$237,001Kwong Yip SumIndividual300,000HK$0.79
09 Feb 22BuyHK$163,415Kwong Yip SumIndividual222,000HK$0.74
08 Feb 22BuyHK$483,616Kwong Yip SumIndividual678,000HK$0.71
07 Feb 22BuyHK$41,400Kwong Yip SumIndividual60,000HK$0.69
04 Feb 22BuyHK$41,400Kwong Yip SumIndividual60,000HK$0.69
31 Jan 22BuyHK$340,949Kwong Yip SumIndividual500,000HK$0.68
28 Jan 22BuyHK$107,360Kwong Yip SumIndividual160,000HK$0.67
27 Jan 22BuyHK$13,420Kwong Yip SumIndividual20,000HK$0.67
26 Jan 22BuyHK$162,024Kwong Yip SumIndividual240,000HK$0.68
25 Jan 22BuyHK$34,500Kwong Yip SumIndividual50,000HK$0.69
24 Jan 22BuyHK$92,460Kwong Yip SumIndividual134,000HK$0.69
21 Jan 22BuyHK$67,060Kwong Yip SumIndividual100,000HK$0.67
20 Jan 22BuyHK$187,767Kwong Yip SumIndividual280,000HK$0.67
19 Jan 22BuyHK$67,000Kwong Yip SumIndividual100,000HK$0.67
18 Jan 22BuyHK$69,000Kwong Yip SumIndividual100,000HK$0.69
17 Jan 22BuyHK$68,800Kwong Yip SumIndividual100,000HK$0.69
14 Jan 22BuyHK$34,500Kwong Yip SumIndividual50,000HK$0.69
13 Jan 22BuyHK$34,500Kwong Yip SumIndividual50,000HK$0.69
12 Jan 22BuyHK$69,000Kwong Yip SumIndividual100,000HK$0.69
11 Jan 22BuyHK$136,480Kwong Yip SumIndividual200,000HK$0.68
10 Jan 22BuyHK$273,679Kwong Yip SumIndividual400,000HK$0.68
07 Jan 22BuyHK$532,037Kwong Yip SumIndividual780,000HK$0.68
06 Jan 22BuyHK$361,672Kwong Yip SumIndividual530,000HK$0.68
05 Jan 22BuyHK$272,001Kwong Yip SumIndividual400,000HK$0.68
04 Jan 22BuyHK$746,036Kwong Yip SumIndividual1,082,000HK$0.69
03 Jan 22BuyHK$533,655Kwong Yip SumIndividual820,000HK$0.65
31 Dec 21BuyHK$283,843Kwong Yip SumIndividual440,000HK$0.65
30 Dec 21BuyHK$359,950Kwong Yip SumIndividual580,000HK$0.62
29 Dec 21BuyHK$548,911Kwong Yip SumIndividual900,000HK$0.61
28 Dec 21BuyHK$424,270Kwong Yip SumIndividual700,000HK$0.61
24 Dec 21BuyHK$514,983Kwong Yip SumIndividual900,000HK$0.57
23 Dec 21BuyHK$270,651Kwong Yip SumIndividual500,000HK$0.54
22 Dec 21BuyHK$257,799Kwong Yip SumIndividual500,000HK$0.52
21 Dec 21BuyHK$306,713Kwong Yip SumIndividual620,000HK$0.49
20 Dec 21BuyHK$333,821Kwong Yip SumIndividual690,000HK$0.48
17 Dec 21BuyHK$376,732Kwong Yip SumIndividual824,000HK$0.46
16 Dec 21BuyHK$236,724Kwong Yip SumIndividual518,000HK$0.46
15 Dec 21BuyHK$372,957Kwong Yip SumIndividual800,000HK$0.47

Ownership Breakdown

What is the ownership structure of 2633?
Owner TypeNumber of SharesOwnership Percentage
Private Companies157,050,0008.2%
Public Companies200,000,00010.4%
General Public344,653,74218.0%
Individual Insiders1,207,918,00063.1%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 8 shareholders own 82.01% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
Kwong Yip Sum
1,171,988,000HK$937.6m0.62%no data
Yunnan Baiyao Group Co.,Ltd
200,000,000HK$160.0m0%no data
Longjin Investments Limited
157,050,000HK$125.6m0%no data
Chun Leung Yim
31,420,000HK$25.1m5.37%no data
Dimensional Fund Advisors LP
5,849,340HK$4.7m-0.01%no data
Yue Wai Pun
3,910,000HK$3.1m76.92%no data
Kwing Tong Lam
600,000HK$480.0k0%no data
Bessemer Investment Management LLC
205,918HK$164.7k0%no data

Company Information

Jacobson Pharma Corporation Limited's employee growth, exchange listings and data sources

Key Information

  • Name: Jacobson Pharma Corporation Limited
  • Ticker: 2633
  • Exchange: SEHK
  • Founded: 2016
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: HK$1.533b
  • Shares outstanding: 1.92b
  • Website:

Number of Employees


  • Jacobson Pharma Corporation Limited
  • Tower 1, Millennium City 1
  • 23rd Floor
  • Kwun Tong
  • Kowloon
  • Hong Kong


TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
2633SEHK (The Stock Exchange of Hong Kong Ltd.)YesOrdinary SharesHKHKDSep 2016

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/10/05 00:00
End of Day Share Price2022/10/05 00:00
Annual Earnings2022/03/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.